CDSCO Issues Guidelines For Registration Of Medical Devices As Voluntary Registration Period Comes To An End

New Delhi : Medical devices in the Class A and B will fall under the licensing regime in a year from now, on October 1, 2022, while the Class C and D will come under the regime a year after that, according to the Central Drugs Standard Control Organisation (CDSCO).

The document was issued by the Organisation to help the industry which has come out with several related queries, many of them basic FAQs, even as the mandatory registration for Class A and B are expected to start in a few days now.

In a guidance document issued for manufacturers and importers for voluntary and mandatory registration of medical devices, the Organisation said that the registration of Class A, B, C and D devices has been kept voluntary for a period of 18 months with effect from April 1, 2020, till September 30, 2021.

Voluntary registration of Class A and B devices shall be followed by mandatory registration for 12 months after the 18 months of Voluntary registration period is over, that is up to September 30, 2022.

“From October 1, 2022 Class A & B devices will fall under licensing regime,” said the guidance document.

Voluntary registration of Class C and D devices shall be followed by mandatory registration for 24 months after 18 months’ voluntary registration period is over that is October 1, 2021 to September 30, 2023. From October 1, 2023 Class C&D devices will fall under licensing regime.

Documents required for registration of medical devices by the manufactures include the name and address of the company or firm or any other entity manufacturing the medical device along with name and address of manufacturing site of medical device; details of medical device; certificate of compliance with respect to ISO 13485 standard accredited by National Accreditation Board for Certification Bodies or International Accreditation Forum in respect of such medical device; and an undertaking duly signed by the manufacturer stating that the information furnished by the applicant is true and authentic.

Documents required for registration of medical devices by the Importers include the name of the company or firm or any other entity importing the medical device; details of medical device; specification and standards of that medical device; certificate of compliance with respect to ISO 13485 standard accredited by National Accreditation Board for Certification Bodies or International Accreditation Forum in respect of such medical device; and free sale certificate from country of origin.

The guidance document also has detailed steps the manufacturers and importers can follow to register non-notified medical devices.

  • Related Posts

    Commissioner FDA reviews enforcement measures

    Srinagar: Commissioner, Food & Drugs Administration (FDA), Jammu & Kashmir, Khalid Jahangir on Thursday held an introductory meeting with senior officers and field functionaries of Drug and Food Wing of the…

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Karnataka High Court Ashwagandha ruling offers interim relief to supplement makers challenging the FSSAI advisory on Ashwagandha extracts. The Karnataka High Court has stayed an advisory issued by the Food…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Commissioner FDA reviews enforcement measures

    Commissioner FDA reviews enforcement measures

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices